Cargando…

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema

BACKGROUND: Patients with hereditary angioedema with C1 inhibitor deficiency or dysfunction have burdensome recurrent angioedema attacks. The safety, efficacy, and health‐related quality of life (HRQoL) outcomes of C1 inhibitor (C1‐INH) prophylaxis (intravenously administered) in patients aged 6‐11 ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aygören‐Pürsün, Emel, Soteres, Daniel F., Nieto‐Martinez, Sandra A., Christensen, Jim, Jacobson, Kraig W., Moldovan, Dumitru, Van Leerberghe, Arthur, Tang, Yongqiang, Lu, Peng, Vardi, Moshe, Schranz, Jennifer, Martinez‐Saguer, Inmaculada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851661/ https://www.ncbi.nlm.nih.gov/pubmed/30968444 http://dx.doi.org/10.1111/pai.13060

Ejemplares similares

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
por: Aygören-Pürsün, Emel, et al.
Publicado: (2010)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2014)

Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
por: Aygören-Pürsün, Emel, et al.
Publicado: (2014)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history
por: Aygören-Pürsün, E, et al.
Publicado: (2013)

Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema
por: Aygören-Pürsün, Emel, et al.
Publicado: (2016)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
por: Soteres, Daniel F., et al.
Publicado: (2021)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
por: Aygören-Pürsün, Emel, et al.
Publicado: (2018)

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies
por: Gower, Richard G, et al.
Publicado: (2011)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey
por: Mendivil, Joan, et al.
Publicado: (2021)

Subcutaneous C1‐Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1‐INH‐HAE
por: Andarawewa, Shimalee, et al.
Publicado: (2021)

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Current challenges and future opportunities in patient‐focused management of hereditary angioedema: A narrative review
por: Grumach, Anete S., et al.
Publicado: (2023)

Epidemiology and treatment of children with hereditary angioedema in Germany: A retrospective database study
por: Prenzel, Freerk, et al.
Publicado: (2023)

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study
por: Riedl, M. A., et al.
Publicado: (2018)

Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2023)

Informed decision‐making in hereditary angioedema prophylaxis
por: Burnette, Autumn Ford
Publicado: (2021)

Long-term prophylaxis of hereditary angioedema with danazol
por: Xu, Yingyang, et al.
Publicado: (2022)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
por: Cohn, Danny M., et al.
Publicado: (2023)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
por: Bowen, Tom, et al.
Publicado: (2010)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
por: Wahn, V., et al.
Publicado: (2012)

Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert(®) (C1-INH) Registry
por: Bygum, Anette, et al.
Publicado: (2016)

Consequences of Misdiagnosed and Mismanaged Hereditary Angioedema Laryngeal Attacks: An Overview of Cases from the Romanian Registry
por: Moldovan, Dumitru, et al.
Publicado: (2018)

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
por: Farkas, Henriette, et al.
Publicado: (2021)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
por: Geba, Daniela, et al.
Publicado: (2021)

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
por: Gower, Richard G., et al.
Publicado: (2021)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s3dq83sin014ujl6qi291l8ee9